Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rituximab: an insider's historical perspective.

A J Grillo-López1

  • 1Medical and Regulatory Affairs Division, IDEC Pharmaceuticals Corporation, San Diego, CA 92121, USA.

Seminars in Oncology
|February 28, 2001
PubMed
Summary

Rituximab is a groundbreaking monoclonal antibody targeting CD20-positive B-cells for non-Hodgkin's lymphoma. It offers a novel therapeutic option, approved for specific lymphoma types, with ongoing research into its full potential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab.

Leukemia & lymphoma·2006
Same author

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy.

Leukemia·2003
Same author

Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils.

Leukemia·2002
Same author

Complement activation plays a key role in the side-effects of rituximab treatment.

British journal of haematology·2002
Same author

Harnessing the power of antibodies for therapeutic applications was a question of time.

Current pharmaceutical biotechnology·2002

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Rituximab is a chimeric mouse/human monoclonal antibody developed for cancer treatment.
  • It targets the CD20 antigen present on malignant and normal B cells.

Observation:

  • Rituximab binds to CD20-positive B cells, mediating cell lysis through complement-dependent and antibody-dependent cytotoxicity.
  • In vitro studies demonstrated Rituximab's ability to induce apoptosis and sensitize chemoresistant lymphoma cells.

Findings:

  • Approved in 1997 by the FDA for relapsed or refractory, CD20-positive, B-cell, low-grade or follicular non-Hodgkin's lymphoma.
  • Rituximab is the first therapeutic monoclonal antibody approved for cancer treatment and the first single agent for lymphoma therapy.

Implications:

  • Further research is needed to fully understand Rituximab's mechanism of action, resistance, and optimal use in combination therapies.
  • Investigating Rituximab's role in multimodality regimens and nonmalignant applications is crucial for expanding its therapeutic utility.

Related Experiment Videos